Phospho-Akt overexpression is prognostic and can be used to tailor the synergistic interaction of Akt inhibitors with gemcitabine in pancreatic cancer

Abstract

BackgroundThere is increasing evidence of a constitutive activation of Akt in pancreatic ductal adenocarcinoma (PDAC), associated with poor prognosis and chemoresistance. Therefore, we evaluated the expression of phospho-Akt in PDAC tissues and cells, and investigated molecular mechanisms influencing the therapeutic potential of Akt inhibition in combination with gemcitabine.MethodsPhospho-Akt expression was evaluated by immunohistochemistry in tissue microarrays (TMAs) with specimens tissue from radically-resected patients (n = 100). Data were analyzed by Fisher and log-rank test. In vitro studies were performed in 14 PDAC cells, including seven primary cultures, characterized for their Akt1 mRNA and phospho-Akt/Akt levels by quantitative-RT-PCR and immunocytochemistry. Growth inhibitory effects of Akt inhibitors and gemcitabine were evaluated by SRB assay, whereas modulation of Akt and phospho-Akt was investigated by Western blotting and ELISA. Cell cycle perturbation, apoptosis-induction, and anti-migratory behaviors were studied by flow cytometry, AnnexinV, membrane potential, and migration assay, while pharmacological interaction with gemcitabine was determined with combination index (CI) method.ResultsImmunohistochemistry of TMAs revealed a correlation between phospho-Akt expression and worse outcome, particularly in patients with the highest phospho-Akt levels, who had significantly shorter overall and progression-free-survival. Similar expression levels were detected in LPC028 primary cells, while LPC006 were characterized by low phospho-Akt. Remarkably, Akt inhibitors reduced cancer cell growth in monolayers and spheroids and synergistically enhanced the antiproliferative activity of gemcitabine in LPC028, while this combination was antagonistic in LPC006 cells. The synergistic effect was paralleled by a reduced expression of ribonucleotide reductase, potentially facilitating gemcitabine cytotoxicity. Inhibition of Akt decreased cell migration and invasion, which was additionally reduced by the combination with gemcitabine. This combination significantly increased apoptosis, associated with induction of caspase-3/6/8/9, PARP and BAD, and inhibition of Bcl-2 and NF-kB in LPC028, but not in LPC006 cells. However, targeting the key glucose transporter Glut1 resulted in similar apoptosis induction in LPC006 cells.ConclusionsThese data support the analysis of phospho-Akt expression as both a prognostic and a predictive biomarker, for the rational development of new combination therapies targeting the Akt pathway in PDAC. Finally, inhibition of Glut1 might overcome resistance to these therapies and warrants further studies.Electronic supplementary materialThe online version of this article (doi:10.1186/s13045-016-0371-1) contains supplementary material, which is available to authorized users.

Therapeutic Potential of Targeting Wnt/β-Catenin Pathway in Treatment of Colorectal Cancer: Rational and Progress

“…In aggregate future challenges should focus on the (1) optimization and evaluation of Wnt/b‐catenin inhibitors; (2) selection of patient who might benefit from therapy; (3) detection of prognostic and predictive markers that can be used to monitor treatment response; (4) targeting of other key signaling pathways (e.g., AKT/PI3K, NOTCH, mTOR pathway) [Maftouh et al, ; Pashirzad et al, ; Massihnia et al, ], in parallel, to overcome cell resistance.…”

PROM2 promotes gemcitabine chemoresistance via activating the Akt signaling pathway in pancreatic cancer

“…Akt activity is tightly controlled: it is activated by growth factors or cellular stress in the cytoplasm, and then recruited to the plasma membrane where it is phosphorylated (at Thr308 and Ser473) [15][16][17] . Phosphorylated Akt then phosphorylates and inactivate BAD, a pro-apoptotic member of Bcl-2 family that initiates the late stages of apoptosis 18,19 . Activated Akt can also phosphorylate Caspase-9 and impair its function in the apoptotic cascade 20,21 .…”

Phosphorylation-Dependent Inhibition of Akt1

“…Akt1 is a prime target for therapeutic intervention due to its involvement in regulating a multitude of cellular pathways [35,36]. Aberrant Akt function has been linked to cancers and a variety of human diseases related to metabolic regulation, immune function, and neurological development [2].…”